| 臺大學術典藏 |
2020-05-25T07:35:05Z |
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
|
Weiss G.J.;Zhang Z.-Y;Chan J;Hughes L;Bobilev D;Su W.-C;Dziadziuszko R;Mita M;de Castro Carpe?o J;Sachdev J;Lu S;Arkenau H.-T;Chia-Chi Lin; Chia-Chi Lin; Arkenau H.-T; Lu S; Sachdev J; de Castro Carpe?o J; Mita M; Dziadziuszko R; Su W.-C; Bobilev D; Hughes L; Chan J; Zhang Z.-Y; Weiss G.J. |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Chia-Chi Lin; Akimov M; Ghebremariam S; Hong D; Poon R.T.P; Azaro A; Lim W.T; Bauer T.M; Nam D.-H; Schuler M; Su W.-C; Bang Y.-J; Zhao S; Giovannini M; Ma B. |
| 臺大學術典藏 |
2020-05-25T06:51:54Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Chiun Hsu; Cheng A.-L.; Yang T.-S.; Shun C.-T.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.; Chen L.-T.; Lin Z.-Z.; Shen Y.-C.; Li C.-P.; Yen C.-J.; Chiun Hsu; Lin Y.-L.; Shen Y.-C.;Li C.-P.;Yen C.-J.;Chiun Hsu;Lin Y.-L.;Lin Z.-Z.;Chen L.-T.;Su W.-C.;Chao Y.;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.; Cheng A.-L.; Jin K.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; YU-YUN SHAO; Su W.-C.; Sandoval-Tan J.; Chiou T.-J. |
| 臺大學術典藏 |
2020-03-24T07:00:40Z |
Factors associated with myocardial infarction after emergency endoscopy for upper gastrointestinal bleeding in high-risk patients: a prospective observational study
|
Wang H.-P.;Lin J.-T.;CHIEN-HUA HUANG;Su W.-C.;Tai C.-M.;Chiang T.-H.;Cheng T.-Y.;Huang S.-P.;Lee C.-T.; Lee C.-T.; Huang S.-P.; Cheng T.-Y.; Chiang T.-H.; Tai C.-M.; Su W.-C.; CHIEN-HUA HUANG; Lin J.-T.; Wang H.-P. |
| 臺大學術典藏 |
2020-03-05T08:16:37Z |
Prothymosin α promotes STAT3 acetylation to induce cystogenesis in Pkd1-deficient mice
|
Chen Y.-C.;Su Y.-C.;Shieh G.-S.;Su B.-H.;Su W.-C.;Pei-Hsin Huang;Jiang S.-T.;Shiau A.-L.;Wu C.-L.; Chen Y.-C.; Su Y.-C.; Shieh G.-S.; Su B.-H.; Su W.-C.; PEI-HSIN HUANG; Jiang S.-T.; Shiau A.-L.; Wu C.-L. |
| 臺大學術典藏 |
2020-03-02T07:41:00Z |
Polythiophene derivative comprising carbazoles as pendant groups for polymer solar cell applications
|
Wang, H.-J.; Chan, L.-H.; Chen, C.-P.; Lee, R.-H.; Su, W.-C.; Jeng, R.-J.; RU-JONG JENG |
